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The COVID-19 pandemic has compelled a relook at public healthcare and the patent systems. It has brought to halt 
livelihoods with devastating consequences to people’s lives national economies. Global health security is at stake as there is 
a need to develop and deploy more vaccines, repurpose medicines and increase medical infrastructure support. Collaboration 
and collective response is imperative at international and national levels. IPR access is crucial in relation to public health. 
Many countries have issued new policies and enacted laws to make it easier for them to supply medicines to their population 
during the pandemic. Compulsory licensing has been used as an important mechanism to open up IP without the permission 
of patent holders. The present study analyses amendments to patent law and IP legislations that are effected from a cross 
country perspective during the pandemic time. It also examines international cooperation in the context of public health and 
IP under the TRIPS Agreement in view of the on-going consultation at the WTO. The study reveals differences in 
approaches to ‘governmental use’ of patents and access to know-how under the statutory framework. Improving the scope of 
use of products and process patents, suspension of patent term extension, consolidating the compulsory licensing 
mechanism, removal of inequity are the predominant aspects that are part of the amendments to patent law in the countries.  
Pandemics like COVID-19 need legislative initiatives to secure healthcare system access for all citizens. Healthcare 
access includes ready availability of basic vaccines, drugs, medical devices and medical infrastructure. There is often a clash 
between access to healthcare as a fundamental right on one hand and the need to award monopolies in the form of IP rights 
as an incentive for innovations from the pharmaceutical industry on the other. Hence, obstacles arise in decision-making to 
balance innovation incentives and ensuring rights to access healthcare. Judicial decision-making and public policy-making 
have been always at the centre stage in earlier epidemics and now in the current pandemic making it imperative for countries 
to protect the health interests of their citizens. 
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The underpinning aspect is the need to consider the 
inalienable values of universal human rights, 
constitutional rights and respect ethical norms in public 
health decision-making. This is paramount to preserve 
trust in healthcare systems. The Declaration of Alma-
Ata, 1978 recognised health as a fundamental right. It 
established primary health care as the route to 
accomplish the goal of Health for All.1 The Declaration 
mentions the need to use global resources to achieve 
the target by the year 2000. Combating infectious 
disease requires coordinated action and it is with ample 
foresight that the need for international cooperation has 
been emphasised in those times itself.  
International organisations have a crucial role to 
play in the global response and also carry out essential 
tasks to ensure coordinated response to meet health 
targets. At an international level the World Health 
Organisation (WHO), a specialized body of UN, is 
responsible for announcing public health measures and 
monitoring the international scenario in this area. The 
announcement of the Public Health Emergency of 
International Concern (PHEIC) in the case of COVID-
19 has opened the implementation of several of the 
initiatives by WHO and by way of its cooperation. 
Solutions to COVID19 also are covered by 
technologies that are patent protected. WHO activated 
a response for the pooling of patents. In May 2020, the 
WHO COVID-19 Technology Access Pool (C-TAP), 
in cooperation with the Government of Costa Rica and 
forty co-sponsors of the ‘Solidarity Call to Action’, has 
called on the global community to take action to 
exchange information, intellectual property and data 
required on a voluntary basis with respect to detection, 
prevention, treatment and response to COVID-19. The 
aim of C-TAP is also to speed up the scale-up of 
production and the elimination of access barriers in 
order to make products globally available.2Global 
health security is a world problem now. International 
Health Regulations mandate that implementation of 
public health measures should not be burdened with 
trade barriers. Alliances such as the Global Alliance on 
Vaccine Initiative, Measles and Rubella Initiative, 
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Global Polio Eradication Initiative and several others 
have provided timely assistance in the access to 
medical technologies.  
The Agreement on Trade Related aspects of 
Intellectual Property Rights (TRIPS) which entered 
into force on 1st January 1995, establishes an 
obligation to lay down the requirements for the 
safeguard and compliance of minimum standards of 
IPR in member states. Members would need to 
facilitate efficient and sufficient protection of IPR 
with a view to remove misrepresentations and barriers 
to foreign trade. The race for the COVID-19 vaccine 
and rivalry between vaccine manufacturers has been 
at the centre of global debate. In October 2020, India 
and South Africa sent a communication (IP/C/W/669) 
to the WTO for the TRIPS council to consider the 
waiving of the enforcement of the provisions in 
relation to copyright (Section I), industrial designs 
(Section 4), patents (Section 5) and undisclosed 
information (Section 7) that would ease out the access 
to COVID19 related technologies.3 Such a transitory 
revocation of intellectual property would also make it 
possible for non-patent holders to manufacture 
required medical devices such as ventilators, masks 
and protective equipment. A temporary waiver would 
prevent countries to bring trade related challenges 
under the WTO Dispute settlement forum against 
countries that grant compulsory licences in response 
to COVID19. Further consultations have been taken 
up and different viewpoints emerged. Developing 
countries argue that there is lock up of technology as 
part of bilateral understanding, limitation of the 
COVAX facility due to disproportionate needs in case 
of developing countries and threat of lawsuits. The IP 
holders believe that instead of a waiver the voluntary 
licensing approach is more suitable.4 Based on the 
meeting in early May 2021, the revision to the 
proposal is being considered. It must be understood 
that a host of non-patent IP are also essential for the 
development of solutions to combat the pandemic. 
The UN Secretary General António Guterres call – 
“Its time for Science and Solidarity” has been timely. 
In its new outreach plan the UN appealed that a 
coordinated approach involving equity will help solve 
the current pandemic. This campaign also addresses 
the aspect of disinformation which negates efforts to 
solve the pandemic. The UN has also launched a 
humanitarian response plan together with UNICEF 
and the WHO.5 The present study examines the 
context of public health and patents in the current 
pandemic situation. It analyses how health directives 
influence invoking of patent legislations from the 
standpoint of how the provisions provide for 
mandatory or permissive aspects. Further, 
amendments in patent law related to governmental use 
and compulsory licensing from a cross country 
perspective are analysed. 
Public health concerns and IP concerns are at cross 
roads in the current pandemic. Arguments have been 
put forward for incentivisation and open access of the 
healthcare technologies alike in the wake of the 
pandemic. 60% of the emerging diseases are zoonotic 
in origin. Response of international health regulations, 
national health systems and local health mechanism 
has an important bearing of the overall measurement 
of the efficiency of a healthcare system. Only 30% of 
the WHO members are compliant with the 
international health regulations.  
 
Global Collaboration to Deal with Pandemic 
Not only technical guidance is technical guidance that 
is required during a disease outbreak but also a need for 
cooperation that is simple and rational. Such a 
framework of cooperation that exists between nations is 
an important mode of dealing with mutual health threats. 
Further, exchanging information and experience on 
pathogen transmission routes, the illness they cause, and 
potential solutions speeds up learning and allows for 
more development. The establishment of rules and 
principles facilitates knowledge comparability, promotes 
best practices and the development of common norms. 
The WHO and its World Health Assembly (WHA) 
serve as a platform for countries to exchange 
knowledge, discuss issues and make joint decisions.6 
The WHO Director General announced the 
epidemic a Public Health Emergency of International 
Concern (PHEIC) on 30th January 2020, based on the 
advice and recommendation of the Emergency 
Committee. From 11th to 12th February 2020, world 
experts on COVID-19 convened at the WHO’s Geneva 
headquarters to determine the existing state of 
understanding regarding the emerging virus, agree on 
scientific questions that must be addressed urgently and 
collaboration opportunities to promote and finance 
priority research to help contain the epidemic (COVID-
19 Public Health Emergency of International Concern 
(PHEIC) Global Research and Innovation Forum). 
Health crisis on global fore can be very challenging 
to not only manufacture vaccines but also ensure their 
equitable distribution and further sharing of clinical 
trial information. International collaboration is also 




needed on advice, technical guidance, response 
research and training. In the absence of an 
internationally binding agreement on equal access, 
pharmaceutical companies may prioritize their own 
interests, favouring more prosperous countries and 
segments of the population. “Vaccine imperialism” 
has become a challenge as some countries demand 
privileged right to vaccinations for their people, while 
others seek to prioritize economic interests for their 
pharmaceutical industries.7 It has been observed that 
the current pandemic would need innovative legal, 
operational and financial strategies, compulsory 
licences, patent pools, advanced business obligations, 
a multinational buying structure, price caps and mixed 
financing.8 
To minimize socio-economic consequences, a 
concerted response and continued demand for 
collaboration on global scale is of utmost importance. 
Multinational organisations such as the WHO are 
crucial.9 Through its work closely with influential 
multi-stakeholder partnerships including the Global 
Alliance for Vaccines and Immunization (GAVI) and 
the Coalition for Disease Preparedness Innovation 
(CEPI) it is coordinating the efforts of the health crisis 
that countries are grappling in the pandemic.10 In 
April 2020, the WHO launched the “Access to 
COVID-19 Resources (ACT) Accelerator,” a global 
collaboration that includes the WHO, CEPI, and 
GAVI, among others, to accelerate the development, 
manufacturing, and distribution of new COVID-19 
therapeutics and vaccines.11It also emphasised that for 
the global supply of the COVID-19 vaccine, 
coordinated national efforts should be planned.  
 
Evolution of COVAX 
The Access to Covid19 Tools (ACT) Accelerator is 
a global partnership aimed at accelerating the growth, 
manufacturing, and equal distribution of COVID-19 
studies, therapies and vaccines. GAVI, the CEPI and 
WHO are leading the COVID19 Vaccine (COVAX) 
facility. COVAX aims to speed up the growth and 
production of COVID-19 vaccines while also ensuring 
equal and balanced access for all countries around the 
world. This is the world’s largest actively controlled 
inventory of COVID-19 vaccine candidates. It provides 
access to a wide variety of vaccine candidates 
appropriate for a range of circumstances and settings to 
self-financing members and those qualifying for 
assistance through the GAVI COVAX Advance 
Market Commitment.12 While the opportunity to 
mobilize vaccination to combat the pandemic is more 
important than ever, collaboration to ensure that greater 
access, information exchange and newer medications 
and medical infrastructure need to be hastened. It 
encourages pooling of patents such that the transaction 
costs could be reduced. This effort is to provide the 
sharing of data, available knowledge and IP. Such an 
effort takes into consideration safety only when all are 
vaccinated and receiving medication as required.13 
Fully self-financing countries (the high income 
countries and upper middle income countries 
representing 53% of the countries) make a direct 
contribution to this facility by agreeing to buy vaccine 
doses for the most vulnerable populations. Countries 
who are funded (the low income countries and low 
middle income countries which are 47% represent 47% 
of the countries) have their financial contributions to 
the facility secured by the process of Official 
Development Assistance.14 COVAX announced in 
January 2021 that it had signed an advance purchasing 
agreement with Pfizer for up to 40 million doses of the 
Pfizer-BioNTech vaccine candidate, which has already 
been approved by the WHO for Emergency Use. The 
timely and fair distribution of vaccinations is not only a 
moral but also a strategic and financial imperative. In 
February 2021, India used the GAVI’s COVAX 
facility to export Covid-19 vaccines to Africa. The 
Serum Institute of India had sent the first batch of 
AstraZeneca/Oxford University-developed vaccine 
shots for the COVAX global inoculation scheme, 
demonstrating its contribution to provide COVID-19 
vaccines.15 By supplying the first batch of COVID-19 
vaccines to Accra, Ghana, marks a part of an ambitious 
attempt to produce at least 2 billion doses of COVID-
19 vaccines by the end of 2021.16COVAX facility has 
the mechanism of voluntary licensing where COVAX 
obtains license from the vaccine producers to distribute 
it to other countries. The 6th Access to COVID19 tools 
(ACT) accelerator facilitation council meeting (on 12 
May 2021) emphasised on the need to step up 
production and increase uptake of COVID19 tools. 
Over 100 countries are being shipped of medical 
facilities. As ‘virus variants’ continue to emerge, health 
sector has been further disrupted The WHO regulatory 
updates sign a positive message of increased 
consultation for global solutions to tackle the new 
strains. To ensure quality assurance, the COVAX 
facility has been advised to consider only those 
products listed by WHO Emergency Use Listing or 
Prequalification or under exceptional circumstances 
products that approved by specified stringent 




regulatory authorities. In the First meeting of the task 
force on COVID-19 vaccines, therapeutics and 
diagnostics for developing countries, the Heads of the 
World Bank Group, International Monetary Fund, 
WHO and WTO emphasised on the urgent need to 
increase supplies of vaccines, therapeutics and 
diagnostics in developing countries and enhance 
sharing of information in deployment of COVID-19 
vaccines. The current context provides a compelling 
need to relook at the importance of the public health 
and IP discussions in relation to the TRIPS 
Agreement.  
 
A relook at Article 31 of TRIPS  
Article 31 of the TRIPS Agreement states, among 
other things, that the individual or company seeking a 
license must have made a good effort to procure a 
voluntary license from the patent holder on equal 
business terms. Only if this fail a compulsory license 
be issued, and the patent owner must receive 
payment. In Article 31(h), there is a mention of 
“economic value of the authorisation” but no metric is 
offered for “adequate remuneration” or “economic 
benefit”. In most cases, acceptable royalties have been 
determined depending on what the patentee has 
offered based on past licenses in similar 
circumstances. It has been observed that such an 
application is imperfect when dealing with foreign 
exports, as prices and uncertainties will escalate the 
price in a huge manner.17 
The need for catering to domestic manufacturing 
has been the hallmark of how governments derive the 
context of opening up of compulsory licensing 
mechanism. Developing nations concerted efforts to 
prohibit patent immunity to enable access to life-
saving medicines had necessitated the need for a post 
TRIPS debate on public health resulting in the Doha 
Declaration.18 
 
Doha Declaration on Public Health 
A significant number of developing countries, 
including the African Community, sent a joint request 
for a special declaration on the TRIPS Agreement and 
access to medicinal products to the IP/C/W/296 
TRIPS meeting, which formed the basis of the Doha 
Resolution. The developing countries in one voice set 
the agenda by emphasizing on the flexibility of 
TRIPS in relation to public health.19 For the first time 
on the WTO record, developed country participants, 
including the European Commission, Japan, 
Switzerland, and the United States, decided in June 
2001 that the TRIPS Agreement provided a number of 
flexibilities, including compulsory, unconditional 
licencing. Some countries tried to restrict the scope of 
the Declaration. In respect to compulsory licences, 
Article 31 of TRIPS states:  
 
“Each Member has the right to allow other use 
of the subject matter of a patent without the 
authorisation of the right holder, including use 
by the government or third parties authorised by 
the government, and to determine the grounds 
upon which such use is allowed”.  
 
More specifically mentioned in the Doha 
Declaration Para 6, recognizes the difficulties faced 
by countries incapable of manufacturing abilities,  
 
“We recognize that WTO Members with 
insufficient or no manufacturing capacities in 
the pharmaceutical sector could face difficulties 
in making effective use of compulsory licensing 
under the TRIPS Agreement.” 
 
Several countries have issued new measures and 
passed legislation to make it easier for them to 
provide drugs to their citizens during the pandemic. 
Compulsory licensing has become a key tool for 
opening up IP without the consent of patent holders. 
Agreements such as the TRIPS along with the Doha 
Declaration have aided the implementation of 
compulsory licensing. It is amply clear that the scale 
of requirements is huge to deal with the current 
pandemic. The need for conditionality and 
governmental exceptions available under patent 
legislations of many countries. In the following 
section, the context of compulsory licensing in light 
of Article 31 of the TRIPS and the status of the 
proposals submitted to the WTO for a partial waiver 
of IP are discussed.  
Monopoly in a patent right is conditional in nature. 
The scope of restrictions depends on patent law of a 
given country. In certain cases, the government may 
compel a right holder to sell his patent to a third party 
in return of adequate royalties. Compulsory license 
allows governments to use the patented product, or 
authorize a third party that is willing do so, without 
the transfer of title. These steps are taken in order to 
implement public health programs that improve low-
income countries access to medicine. Compulsory 
licensing has the effect of increasing competition, 
improving medicine access and potentially lowering 
costs. This has been invoked in the case of 
pharmaceuticals where public access of the technology 




takes precedence over the patent holder’s reserved 
interests and proprietary right to use it. The Doha 
Declaration reaffirmed governments’ absolute right to 
take steps to protect public health by requiring WTO 
member countries to issue compulsory licenses to 
export generic versions of patented medicines to 
countries with insufficient to no manufacturing 
capability. COVID-19 vaccine research, approval, and 
production are moving at a breakneck pace. Many 
national vaccine programs are being thrown into 
disarray as a result of setbacks, prompting demands to 
policymakers and suppliers to work together to boost 
demand. To improve the availability of potential 
vaccines, several pharmaceutical firms, including 
AstraZeneca, have concluded sub-licence agreements 
with many manufacturers, including the Serum 
Institute of India. Gilead has already granted its 
Remdesivir patents to generic manufacturers in India, 
Pakistan, and Egypt, allowing them to sell the drug in 
127 countries. 
Compulsory licensing bases public interest central in 
determining such a grant. In the current situation, 
where the pandemic has afflicted people from all walks 
of life, there is an urgent need for medication and/or 
vaccine to fight COVID 19. It is also reasonable that 
patentee can be reasonably compensated for the IP in 
view of the significant investment in development of 
technology. Voluntary licensing mechanism either on 
an individual basis or in a coalition form has led to 
some access of technologies during the pandemic time. 
But as the world grapples now with ‘variants of 
concern’ and a crippling healthcare system there is a 
compelling need for opening up access to technologies 
to a greater extent.  
 
WTO Waiver and Opening Up IP to Meet Public Health 
Requirements 
Countries have refrained from arbitrarily suspending 
IP rights in their respective jurisdictions. WTO has 
served as a platform for organizing policies 
surrounding intellectual property rights (IPRs) to allow 
greater access to technologies. Under the WTO waiver 
for IP, countries are discussing the merits of waiving 
the adoption, operation, or compliance of Sections 1 
(copyright), 4 (industrial designs), 5 (patents) and 7 
(undisclosed information) of Part II of the Agreement 
on Trade Related Aspects of Intellectual Property 
Rights (TRIPS) in relation to COVID-19 avoidance, 
containment, or care for a given duration, in response 
to a proposal submitted by India and South Africa. 
India, known as the pharmaceutical hub of the world 
because it supplies vaccines to more than seventy 
countries on a humanitarian and economic basis, is 
leading the proposal for a temporary TRIPS waiver for 
IP at the World Trade Organization (WTO). If India is 
successful in obtaining the planned TRIPS waiver, 
vaccine costs will be significantly reduced, allowing 
free flow of drugs and quick technology transition 
around the world. However, since many western 
nations are opposed to the decision, having the plan 
cleared and forming consensus is not going to happen 
soon enough. Their interests in view of patent linkage 
in Asia would be also affected.20 India and South 
Africa's initiative received an impetus when a coalition 
of least developed countries (LDCs) recently endorsed 
it. So far, approximately ninety countries have openly 
supported this wavier. A revised decision text was 
published on 25th May 2021, which urged the WTO to 
also consider the emergence of the new variants of the 
SARS-COV2 virus, effect on children, the need to 
deploy ‘health products and technologies’ taking into 
consideration IP issues. The objectives set forth in 
Article 7 of the TRIPS Agreement define the essence 
of how IPRs should be realised i.e., to promote 
technological innovation, promote dissemination of 
technology taking to consideration rights and 
obligation. Further, Article 8 emphasises on the need to 
formulate and amend laws and regulations to enable 
protection of public health and nutrition and sectors of 
vital importance for socio-economic and technological 
developments. It is amply evident that the joint 
implementation of both these in the pandemic needs to 
be considered with the wider approach of securing 
health technologies access. The need for justifying IPR 
in relation to these articles should be consistent with 
the existing realities.  
Accessibility, affordability and availability need to 
continue to be the hallmark of providing health justice 
in these times of the pandemic. A dedicated effort to 
improve rights for public is emphasised by WHO and 
various international collaborations percolating down 
to the individual countries. Till the time we have a 
coordinated response under the WTO countries need to 
depend on domestic measures and existing 
international cooperation. Compulsory licensing proves 
to be a quick fix to provide equitable access to 
medicines and health related drugs during emergencies. 
The Patents Act, 1970 of India has provisions to 
implement it when the need arises. Some patent holders 
freely licence their drugs to generic producers in order 
to increase access. This is achieved either directly 




between patent holders and generic producers or 
enabled by organisations such as the Medicine Patent 
Pool. Voluntary licenses, on the other hand, are often 
used to limit the geographical areas where the licensed 
commodity can be sold.21 Compulsory licenses could 
be an ideal choice for certain countries to increase 
access to patented medication where there is no 
provision or jurisdiction to obtain a voluntary license 
for a particular medicine. Price reduction of patented 
medicine under compulsory licencing is known and is 
stipulated to balance interests of the patentee. It is clear 
that effect of compulsory licencing will rely on the 
further refinement of procedures to promote its 
application, growth of technical and manufacturing 
technologies in developed nations, and the value of 
life-saving drugs.22 The usefulness of compulsory 
licencing threats in agreements with patent holders as a 
mechanism to lower drug costs is commonly known.23 
Some studies indicate that compulsory licencing has 
been a successful way for obtaining price increases for 
patented pharmaceutical products.24 It has been 
observed that alternative measures can be more 
successful than the actual issuing of compulsory 
licences, such as cost bargaining and voluntary 
licencing agreements.25 There are certain limitations in 
the two methods i.e. compulsory licencing and 
voluntary licencing. Compulsory licencing is often the 
only option when patent holder does not reduce price 
or is not willing to grant a voluntary license.26 Further, 
regional or economic restrictions and certain arbitrary 
licence conditions enforced by pharmaceutical firms 
reduce the feasibility of voluntary licencing.27 
The developing countries, most often, are the ones 
prompt in invoking compulsory licensing as a timely 
response to solve difficulties faced due to lack of 
access of a patented product. As a global response, it is 
desirable that the WTO and WHO open up IP to pool 
information that would be beneficial globally. The 
threat of compulsory licensing nevertheless is essential. 
It makes sense for a country to grant a compulsory 
license to purchase a prescription drug for a health 
condition only where there are potential existing 
generic manufacturers or prospective generic 
producers. While international cooperation is a 
requirement for dealing with the existing crisis, 
national efforts are key to implementation of health 
mandates. Implementation of national legislative 
responses to health emergencies not only support 
domestic measures but also provide opportunities for 
cooperation in a cross country context. 
Cross-Country Response during Pandemic 
Pandemic response is multifaceted. Health equity has 
become the most debated aspect and certainly there are 
inequalities in this regard. During the pandemic several 
countries had made amendments to the patent legislation 
and/other relevant legislations to enable governments to 
provide access to patented medicines and medical 
infrastructure. Cross country analysis of the amendments 
to patent legislations and other laws provides an 
important context to understand national policy 
considerations and preparedness. In the following 
section, individual country responses are discussed. 
On 25th March 2020, Canada introduced the 
“COVID-19 Emergency Response Act” as a legislature 
enabling a patented technology to be created, marketed, 
and used by the Canadian state. Under Part 12 and 
Section 51 amendments have been effected in the Patent 
Act. Under the current legislation, a manufacturing 
licence may be granted without first consulting with the 
holder of the IP or possessing the capacity to 
manufacture locally, but the patentee must be paid. 
Under the current Section 19.4 of the Canadian Patent 
Act, the government may grant compulsory licences to 
third parties if the Minister of Health confirms a national 
emergency28 prior to 30th September 2020.  
 
Application by Minister 
 
19.4 (1) The Commissioner shall, on the 
application of the Minister of Health, authorize 
the Government of Canada and any person 
specified in the application to make, construct, 
use and sell a patented invention to the extent 
necessary to respond to the public health 
emergency described in the application. 
 
Contents of application 
 
(2) The application must 
(a) set out the name of the patentee and the 
number, as recorded in the Patent Office, of 
the patent issued in respect of the patented 
invention; 
(b) include a confirmation that the Chief Public 
Health Officer, appointed under subsection 
6(1) of the Public Health Agency of Canada 
Act, believes that there is a public health 
emergency that is a matter of national 
concern; 
(c) include a description of the public health 
emergency; and 
(d) specify a person, if any, that is to be 
authorized to make, construct, use and sell 




the patented invention for the purposes of 
responding to the public health emergency. 
(emphasis added) 
 
The Canadian Government has no obligation to 
negotiate with the patent holder before granting a 
license to a third party to manufacture a medicine. 
The patentee would be compensated with the 
adequate remuneration as determined by the 
Commissioner taking into the circumstances, 
economic significance of the authorization and the 
extent to which the patented invention is produced, 
built, used, and sold. 
In case of France, on 23rd March 2020, a new law 
‘Emergency Law No. 2020-290’ was passed that 
brought in amendments to the Public Health Code. 
Title 1 deals with State of Health Emergency (Article 
1 to 8). Several amendments were effected to improve 
health protection, health administration and 
transparency in dealing with the pandemic. Subject to 
the declaration of the State of health emergency as 
outlined in Article 1, Article 2 of the Code brings in 
measures to deal with health threats and deal with 
crisis. The Prime Minister can exercise price 
regulation under Article L.3131-15 and take measures 
for manufacture of drugs to combat the health 
emergency.  
 
Article L3131.15. In the territorial districts 
where the state of health emergency is declared, 
the Prime Minister may, by regulatory decree 
taken on the report of the Minister responsible 
for health, for the sole purpose of guaranteeing 
public health 
8. Take temporary measures to control the 
prices of certain products made necessary to 
prevent or correct the tensions observed on 
the market for certain products; the 
National Consumer Council is informed of 
the measures taken in this direction; 
9. As necessary, take any measure allowing the 
provision of the patients of appropriate 
drugs for the eradication of the health 
disaster; 
 
Article L613-16 and Article L613-17 of the French 
Intellectual Property Code provide for a compulsory 
non-exclusive license. Under Article L613-16, the 
three conditions of no agreement reached with patent 
holder, patented protecting the invention must be a 
medical product process of obtaining it and invoking 
administrative or Court decisions in conditions of high 
pricing or insufficient products available must be met.  
Some of the advanced countries which have been a 
hub for manufacturing have also sought to amend 
their patent law in the wake of the pandemic. In case 
of Germany, Section 13 of the German Patent Act 
provides for use of an invention for public welfare.  
 
As per Section 13 of the Act,  
 
(1) The patent does not have any effect if the 
Federal Government orders that the 
invention be used in the interests of public 
welfare. Furthermore, it does not extend to a 
use of the invention that is ordered in the 
interest of federal security by the competent 
highest federal authority or on their behalf 
by a subordinate body. 
 
The Federal Administrative Court is responsible for 
dealing with matters related to patent contests by 
resolving disputes and in conditions of the need for a 
mandatory licensing ensure appropriate remuneration 
from the federal government to the patent holder. 
Germany passed the Prevention and Control of 
Infectious Diseases in Humans Act on 28th March 
2020, authorising rolling out of compulsory licensing. 
Under Section 5(2) ofthe Epidemic Protection Act, 
the Federal Ministry of Health is authorised to address 
the epidemic situation keeping in view national 
considerations. There is a greater scope of the ‘use 
orders’ in view of a parliament-declared nationwide 
crisis that goes beyond Section 13 of the German 
Patent Act. 
In the case of Israel, under Article Three: Use of 
Inventions in the Interest of the State, Sections 104 
and 105 of Israel's Patents Law 5727-1967 authorise 
compulsory licences to be granted by the government 
if the Minister “finds that this is required in the 
interests of national security or the protection of vital 
supplies and services”. 
 
Section 104 Right of State to exploit invention- 
 
104. The Minister may permit the exploitation of 
an invention by Government departments or 
by an enterprise or agency of the State, 
whether a patent for it has or has not 
already been granted or has not already 
been applied for, if he finds that that is 
necessary in the interests of the National 
security or of the maintenance of essential 
supplies and services. 
Section 105 Right of State to permit exploitation of 
invention-  





105. The Minister may, if he finds that that is 
necessary for the purposes enumerated in 
section 104, grant a permit under that 
section to a person who operates under 
contract with the State, in order to ensure or 
facilitate the implementation of that contract 
and for the requirements of the State 
only.”(emphasis added) 
 
On 18th March 2020, Israel issued a compulsory 
licence to receive the generic versions of the HIV/AIDS 
antiretroviral drug Kaletra. This drug is a mixture of 
AbbVie’s antiviral medications lopinavir and ritonavir. 
Kaletra's patent expires in Israel only in 2024. This drug 
is off patent in many countries including India. The 
issuance of this permit by the Health Ministry provided 
an opportunity to import generic versions of Kaletra 
only for treatment of COVID-19. In response to the 
issuance, AbbVie immediately announced it would not 
impose its patent rights on Kaletra. In the pandemic 
time, this is one example of how invoking a compulsory 
licensing has eased out the use of generics to deal with 
the potential health crisis.  
Chile passed a decree (on 7th March, 2020) that was 
published in the Official Gazette by which the Ministry 
of Health, Chile declared ESPII, a Sanitary Emergency 
due to a Public health emergency of International 
Importance, in view of the outbreak of the SARS COV-
2 virus. On 17th March, 2020, the Chilean Chamber of 
Deputies adopted the “Resolution 896 2020”. Part III (2) 
of the Resolution mandates the Minister of Health to 
grant non voluntary licenses with respect to medicines 
and medical infrastructure that is necessary to prevent, 
diagnose and treat COVID-19.  
 
Part III. 2. REQUIRE: ………...for the granting of 
non-voluntary licenses provided in Article 51 No. 2 
of Industrial Property Law No. 19.039, regarding 
all patent applications and issued patents related 
to vaccines, drugs, diagnostics, devices, supplies, 
and other technologies useful for the surveillance, 
prevention, detection, diagnosis and treatment of 
persons infected with the coronavirus SARS-CoV-
2, for public health grounds. 
 
Further, under Part III of the resolution the Minister 
of Health is further required prepare a report on the 
existence of patents and other industrial property rights 
as determined by the National Institute of Industrial 
Property. The assessment of intellectual property status 
would help to know whether or not there are 
restrictions to import or manufacturing in Chile. 
It is interesting to note that very early in the pandemic 
time, Chile has not only recognized the need to open up 
IP but also emphasized through this Resolution that 
there is also a need for access to information from the 
WHO Global Observatory. 
 
4. TO REQUIRE the Minister of Health to 
request the World Health Organization 
(WHO) Global Observatory on Health R&D 
to collect information on the research and 
development costs directly associated with 
vaccines, drugs, diagnostics, devices, supplies, 
and other technologies useful for the 
surveillance, prevention, detection, diagnosis 
and treatment of COVID-19, including the 
investments made by public sector institutions, 
private sector institutions, and charities. 
 
Australia along with other countries submitted a 
communication (IP/C/W/671) to the proposed 
discussions on WTO waiver of IP. On 27thFebruary, 
2020, the Intellectual Property Laws Amendment 
(Productivity Commission Response Part 2 and Other 
Measures) Act 2020 was introduced in Australia that 
brought in several changes including the phasing out of 
the innovation patent system. This phase out will begin 
from 26th August, 2021.Further, the scope of the 
provisions in relation to Crown use and the compulsory 
licence were expanded.  
Intellectual Property Laws Amendment (Productivity 
Commission Response Part 2 and Other Measures) Act, 
2020 introduced Section 160Ainto Australian Patent 
Act, 1990: 
 
160 A When an invention is exploited for Crown 
purposes 
(1) An invention is exploited for Crown purposes 
if: 
(a) the invention is exploited for the services of a 
relevant authority; and 
(b) the exploitation is by: 
(i) the relevant authority; or 
(ii) if a person is authorised, in writing, by the 
relevant authority for the purposes of this 
subparagraph—the person for the relevant 
authority. 
 
This introduced provision for crown use would 
allow governments to exploit patented inventions in 
certain conditions, without infringing patent rights. 
The Section 163(3) of the Patents Act sets out several 
conditions. First, the approval of an authorisation for 
use of a patented invention will be given when efforts 
have failed to obtain a license. The time period of at 




least 14 days would be given by the relevant authority 
for the exploitation of the invention for crown 
purposes. The relevant authorities include 
Commonwealth, State and Territory jurisdictions. 
Commonwealth and States can utilise ‘Crown use’ to 
facilitate the urgent manufacture of medical supplies 
for use in the treatment or prevention of COVID-19 
infection.  
Indonesia is one of the countries that is supporting 
the WTO waiver proposal for opening up of IP for 
solutions for COVID-19. In the preamble of the patent 
law, public purpose in relation to patents is indicated 
as ‘that patents are intellectual property granted by 
the state to inventors for the results of their inventions 
in the field of technology which have a strategic role 
in supporting national development and advancing 
public welfare.’ 
Under the Patent Law No. 13 of 2016, Article 1 
(15) outlines the context of governmental use of a 
patent. 
 
15. Rewards are compensation received by a 
party entitled to obtain a Patent for an 
invention produced, in a working relationship 
or an invention produced by either an 
employee or a worker who uses the data 
and/or facilities available in his work even 
though the agreement does not require him to 
produce the invention. or the patent holder of 
an invention produced by an inventor in an 
official relationship or the patent holder of a 
compulsory licensee or a patent holder of a 
patent that is operated by the government. 
 
In Indonesia, a third party can file an application 
for a compulsory license pursuant to Article 82 if an 
invention is not worked within thirty-six months of 
grant. On 2th November 2020, the President of 
Indonesia passed the Omnibus Law on Job Creation 
through Law No.11 of 2020 concerning Job 
Creation (called the “Job Creation Law”), which also 
took effect on the same day. Under Chapter VI, on 
Ease of doing Business, Article 107 of the Job 
Creation Law amends certain provisions in the Patent 
Law No. 13 of 2016. Article 20 of the Patent Law 
obliged patent holders to manufacture the product or 
use the process in Indonesia within 3 years of grant 
date. Under the new regulation, Regulation No. 14 of 
2021, patent owners cannot postpone the working of 
their patent invention under Article 20.  
Brazil has been supporting the recent IP waiver 
proposition at WTO. Three new bills, Bills 1184 of 
2020, 1320 of 2020 and 1462 of 2020, were proposed 
in Brazil for the grant of compulsory licensing during 
the pandemic. The Bill 1184 of 2020 seeks to allow 
the compulsory licensing of patents by the Federal 
Government during the state of health emergency 
established by Law No. 13.979 of February 6. The 
Bill 1320 of 2020 seeks to eliminate delays in the 
grant of compulsory licenses leading to an automatic 
application under the state of public health 
emergency. Three conditions that need to be 
considered in such cases are validity of the license for 
duration of the public health emergency, remuneration 
of the patent holder fixed at 1.5% of the sale price to 
the Government and titleholder of the compulsory 
licensed patent or patent application will be obliged to 
provide to the Government all necessary and 
sufficient information for the effective reproduction 
of the technologies. The Bill 1462 of 2020 seeks to 
amend the compulsory licensing provisions of Article 
71 of Law No. 9279/1996 of the Industrial Property 
statute. The objective is to include the option of 
invoking national or international emergency status. 
 
Article 71 of the Law No. 9279 of May 14, 1996: 
 
71. In cases of national emergency or of public 
interest, as declared in an act of the Federal 
Executive Power, and provided the patent 
holder or his licensee does not fulfil such 
need, a temporary and non-exclusive 
compulsory license for exploiting the patent 
may be granted, ex officio, without prejudice 
to the rights of the respective titleholder. 
 Sole Paragraph. The act of granting the 
license shall establish its term and the 
possibility of extension. 
 
From an Indian standpoint, along with S Africa and 
others it is participating in the consultations on the 
temporary waiver of IP at the WTO forum. In the 
recent case29 of 22ndApril, 2021 the Delhi High Court 
ordered the government of the national capital 
territory of India and others to respond to several 
aspects on its preparedness to deal with medical 
oxygen supplies, on the need to invoke compulsory 
licenses under Section 84, utilise special provisions 
for compulsory licenses or notification by the Central 
government under Section 92 and use of inventions 
for government purpose under Section 100 of the 
Patents Act, 1970. Subsequent to this, the Supreme 
Court on its own motion in the case decided30 by a 
three judge Bench on April 30th 2021 urged the 




Central Government to invoke the provisions of the 
Patents Act 1970 to open up the access to patented 
medicines and provide an opportunity for generic 
manufacturers to manufacture the drugs and device 
needed for dealing with the pandemic. The Court 
emphasised on the need to make vaccines and 
essential drugs at affordable prices among other 
aspects. NatcoPharma Limited has filed for a 
compulsory license under Section 92 (1) read with 92 
(3) of the Patents Act 1970. This license is to  
produce Baricitinib which is under patent  
protection in India. Incyte Holdings Corporation holds 
the patent for the same. Unmet needs such as 
restricted availability and excessive price are the 
grounds used for invoking compulsory licensing. 
Natco was given emergency use authorisation by the 
CDSCO to manufacture Baricitinib for use against 
COVID-19. Even as the application was pending Eli 
Lily entered into a voluntary licensing deal with 
Natco whereby it provided a royalty-free, non-
exclusive voluntary license for manufacturing and 
commercialisation of the drug. Eventually, Natco 
withdrew its compulsory license application from the 
Indian Patent Office. 
 
The analysis of the cross country changes to Patent 
Law during the pandemic time has implications from 
the context of public health. In the first quarter of the 
pandemic many countries enacted legislations that 
would help governments invoke emergency 
provisions for use of patents to initiate public health 
measures. This displayed their preparedness ahead of 
the pandemic spread. In the second quarter of 2020, 
coalition on pandemic solutions for pooling 
technologies and the call for suspension of patent 
rights gained ground. Voluntary licensing 
opportunities were opened up on various vaccines  
and drugs. In the last quarter WTO consultation  
for IP waiver was initiated. As the pandemic 
continues to rage across countries with devastating 
proportions and with variants emerging, there is only 
consideration that countries need to think – access to 
technologies and access to information to deal with 
the pandemic.  
 
Conclusion 
Resolving pandemic crisis has been the primary 
concern for all those involved in identifying solutions. 
Institutional competence has been under challenge 
across the world in dealing with such a situation. 
Response is the key and time is the essence. The 
importance of world fora that directly or indirectly deal 
with public health is paramount. The development of a 
collective and coordinated effort for vaccines, 
medicines, medical infrastructure, sharing know-how 
and enhancing their availability and accessibility under 
the WHO is an important development. For more than 
10 months the COVAX facility has aided access to 
medicinal products and test kits to various countries 
and helped in pooling technologies to deal with the 
global health crisis. The WHO’s leadership is critical in 
persuading individual nations to provide access to 
technologies as well as participate in the collaboration 
and cooperation. Further, the need for information 
sharing on outcomes is paramount for repositioning 
COVID19 solutions and approaches. It is time that 
WHO revisits the International Health Regulations for 
suitable amendments.  
 
The temporary waiver of IP proposal to WTO 
initiated by India and S. Africa supported by  
many countries is a very important development 
considering the circumstances. Proponents for 
suspending IP rights and those who advocate for 
protection of IP rights have their respective 
arguments. The urgent need for access of technologies 
is what demands a need to focus on ways to enable IP 
use for public health. Nations have a combined 
responsibility. Local scarcity of vaccine and low 
income countries not having access to vaccine is a 
serious concern. It is not unreasonable to expect WTO 
to act in an urgent manner. With new ‘variants of 
concern’ of the virus developing, the demand for 
diversified access to medicines, diagnostics and 
therapies is increasing by the day. The ‘text based 
negotiations’ under the WTO would need to take into 
consideration the mandates of WHO. The enormous 
effort of the Doha Declaration on Public Health 
would become meaningless unless its underpinnings 
are considered. The ‘gestation period’ continues on 
the negotiations. It is time to see whether ‘public 
interest’ will be served from the point of view of 
Article 8 of TRIPS agreement. The World Intellectual 
Property Organisation (WIPO) needs to take forward 
the context of ‘development dimension’ in the context 
of the pandemic as well. In the recent years, WIPO 
has enabled access to technologies by negotiating 
treaties to promote access of IP. It is expected that 
WIPO play a leading role in promoting discussions on 
access to IP for public health purposes.  
 
Another important area of focus is national 
response. As witnessed parallel responses by 




countries in the early part of the pandemic is a 
positive development. There are general conditions  
as well as specific conditions in patent law that 
prevent the abuse and undue enrichment of  
monopoly by the patentee. Analysis of the cross 
country legislative response indicates to the  
expansion of the ‘governmental use’ clause by 
amendments to patent legislations to take care of 
public health measures. In certain countries the 
amendments reflect the scope and coverage of access 
to not only medicines and vaccines but a whole range 
of medical infrastructure. Preparedness is the key to 
remove constraints in implementation of such 
measures. The amendments are not only to IP 
legislations but also to the health related laws as well. 
The role of individual governments measures to deal 
with pandemic provisioning, need to utilise generics 
and provide for local decision making is paramount. 
As urgency is the key, interdependency between 
countries is necessary to address composite solutions 
for COVID-19. A significant part of the solutions to 
the COVID-19 are covered by IP rights. Arguments 
for reasonable compensation for sharing IP are 
relevant. Access to IP is an urgent requirement in 
current circumstances. There cannot be second 
thoughts about this fact.  
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